BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 29500170)

  • 1. Transplant strategies in relapsed/refractory Hodgkin lymphoma.
    Shah GL; Moskowitz CH
    Blood; 2018 Apr; 131(15):1689-1697. PubMed ID: 29500170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel agents positively impact chemotherapy and transplantation in Hodgkin lymphoma.
    Dahi PB; Moskowitz CH; Giralt SA; Lazarus HM
    Expert Rev Hematol; 2019 Apr; 12(4):255-264. PubMed ID: 30874456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
    Martino M; Festuccia M; Fedele R; Console G; Cimminiello M; Gavarotti P; Bruno B
    Expert Opin Biol Ther; 2016; 16(3):347-64. PubMed ID: 26652934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
    Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
    Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
    Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
    Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
    Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of relapsed and refractory Hodgkin Lymphoma.
    von Tresckow B; Moskowitz CH
    Semin Hematol; 2016 Jul; 53(3):180-5. PubMed ID: 27496309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
    Othman T; Herrera A; Mei M
    Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
    Mediwake H; Morris K; Curley C; Butler J; Kennedy G
    Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.
    Deau B; Amorim S; Perrot A; Quittet P; Cornillon J; Chaoui D; Marolleau JP; Oberic L; Le Du K; Fornecker LM; Tournilhac O; Veillard AS; Chaillol I; Robin M; Tamburini J; Brice P
    Br J Haematol; 2018 May; 181(3):341-349. PubMed ID: 29611187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.
    Kopińska A; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kata D; Włodarczyk M; Helbig G
    Pathol Oncol Res; 2021; 27():1609867. PubMed ID: 34385892
    [No Abstract]   [Full Text] [Related]  

  • 12. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.
    Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Peggs KS; Blaise D; Afanasyev B; Diez-Martin JL; Sierra J; Bloor A; Martinez C; Robinson S; Malladi R; El-Cheikh J; Corradini P; Montoto S; Dreger P; Sureda A
    Br J Haematol; 2018 Apr; 181(1):86-96. PubMed ID: 29468647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current approaches to the management of pediatric Hodgkin lymphoma.
    Freed J; Kelly KM
    Paediatr Drugs; 2010 Apr; 12(2):85-98. PubMed ID: 20218745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment-Resistant Hodgkin Lymphoma: Defining the Role of Autologous Transplantation.
    Blum KA
    Cancer J; 2018; 24(5):244-248. PubMed ID: 30247260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose chemotherapy and autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: Emerging questions, newer agents, and changing paradigm.
    Akhtar S
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):272-276. PubMed ID: 28641095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic Stem Cell Transplantation and Brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large-Cell Lymphoma.
    Ishizawa K; Yanai T
    Adv Ther; 2019 Oct; 36(10):2679-2696. PubMed ID: 31392578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.
    Chen R; Palmer JM; Thomas SH; Tsai NC; Farol L; Nademanee A; Forman SJ; Gopal AK
    Blood; 2012 Jun; 119(26):6379-81. PubMed ID: 22611160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?
    Khan N; Moskowitz AJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):227-233. PubMed ID: 28488185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy.
    Moskowitz AJ; Herrera AF; Beaven AW
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():477-486. PubMed ID: 31099645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.